Editor's Queries

Items noticed during assembly that look like research or transcription errors, or ambiguities, in the source chapters. Per the assembly brief they were left as found (with one disclosed exception) rather than fixed silently.

1. Misspelt source domain in Part V. One in-text citation (§1.2.6) and reference [59] use the URL australianprescriban.tg.org.au — presumably a typo for australianprescriber.tg.org.au. Left as found.
2. Truncated links in Part V’s reference list. References [77], [82] and [138] end mid-DOI (e.g. 10.1016/S1474-4422(20)). The in-text citations carry the full DOIs; only the end-list entries are truncated.
3. One duplicated sentence removed. Part V’s preventive-treatment introduction contained the same framing sentence twice in a row (“Before the drug-by-drug detail, three structural facts…”). The duplicate was removed as pure smoothing — no wording of the surviving sentence was changed. Disclosed here for transparency.
4. Part IV reference-list numbering irregularities. The list uses entries 24b and 25b and jumps from 55 to 57 (there is no [^56]). Footnote markers of the form [^n] are used in the text against a plain numbered list, so they will not render as live footnotes in most Markdown renderers. Left as found.
5. Citation/label mismatch in Part VI. Reference [88] is labelled with the Danish Cluster Headache Survey URL but is used to support the “no energy-drink/caffeine trials exist” absence claim. The label and the claim do not obviously match.
6. Suspect URL in Part V, §4.2.7. The Realeve FDA Breakthrough-Device announcement is cited at a realeve.net URL whose slug reads “15-best-blogs-to-follow-about-web-design” — likely a mis-scraped link; the claim itself is corroborated by the surrounding BusinessWire citations.
7. Internal cross-reference drift in Part V. Some of the chapter’s internal pointers (“see §1.5”, “§1.6”, “§4.1”, “§6”) reflect an earlier numbering of its own sections (e.g. §5.1.2’s subsections are numbered 1.2.1–1.2.6). Renumbering was not attempted, to avoid introducing new errors; navigate by heading text.
8. Ambiguous questionnaire n. The differing participant counts for the International Cluster Headache Questionnaire (1,604 / >3,000 / ≈3,251) are logged as Unresolved Conflicts item 10; flagged here too because it may simply be an under-specified description in one or more chapters rather than a true contradiction.
9. Part I colophon scope. Part I–III’s closing colophon (“Compiled from PubMed/PMC…”) describes the four research memos behind the original Chapter 1 only; it does not cover Parts IV–VII, which disclose their own sourcing limitations inline (see especially Part V’s “Sourcing limitations” and Part VII’s registry-coverage notes).
10. Diagram merges. The assembly brief permitted regenerating diagrams that merge cleanly. None did — the Part I attack-mechanism diagram, Part IV’s classification/conversion Mermaid diagrams, Part V’s decision tree and Part VII’s Gantt/model diagrams cover different ground — so all were retained unchanged.